FIELD: pharmaceuticals.
SUBSTANCE: invention relates to compounds of formula (I), as well as pharmaceutical compositions, crystals of (2S)-2-[(3S)-4-{[(3S,4R)-4-(4-chloro-2-fluorophenyl)-1-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-yl]carbonyl}-3-methylpiperazin-1-yl]-3-(2-fluoro-4-methylphenyl)propanoic acid and a method of preventing and treating diseases of urinary bladder and/or urinary tract.
EFFECT: obtaining novel compounds of formula (I) having agonistic effect on melanocortin receptor 4 (MC4 receptor) suitable for treating mediated diseases.
25 cl, 76 tbl, 101 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION | 2015 |
|
RU2669806C1 |
| SUBSTITUTED HETEROCYCLIC SULPHONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | 2014 |
|
RU2675792C2 |
| PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
| FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS AND USE THEREOF | 2017 |
|
RU2732127C1 |
| 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | 2015 |
|
RU2702106C2 |
| MELANOCORTIN RECEPTOR AGONISTS | 2007 |
|
RU2411240C2 |
| NOVEL AMIDE DERIVATIVE FOR INHIBITING GROWTH OF CANCER CELLS | 2008 |
|
RU2434010C2 |
| COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | 2013 |
|
RU2666530C2 |
| COMPOUNDS AND METHODS FOR ENHANCING DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES, USING E3 UBIQUITIN LIGASE | 2013 |
|
RU2781452C2 |
| GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2664533C2 |
